Search

Berkley A Lynch

from Cambridge, MA
Age ~63
Get Report
Also known as:
Berkley N Lynch, Barbara A Lynch, Lynch Berkley
Phone and address:
496 Green St, Cambridge, MA 02139
(617) 576-0032
Related to:
Randall N Swadlow, 67
Connected to:
Aisha C Lynch, 50Alena J Lynch, 66Alex D Lynch, 38Alexandra J Lynch, 39Alfred T Lynch, 68Allison Lynch, 33Alyse B Lynch, 35Amara T Lynch, 35Amy R Lynch, 41Andi J Lynch, 43

Berkley Lynch Phones & Addresses

  • 496 Green St, Cambridge, MA 02139 (617) 576-0032
  • 129 Franklin St, Cambridge, MA 02139 (617) 621-9762
  • Oakland, CA
  • 496 Green St, Cambridge, MA 02139

Work

Company: Vigil neuroscience Aug 2020 Position: Vice president, biology

Education

School / High School: University of California, Berkeley 2013 to 2016

Skills

Drug Discovery • Biochemistry • Molecular Biology • Biotechnology • Assay Development • Biomarkers • Pharmacology • Drug Development • Neuroscience • Pharmaceutical Industry • Cro • High Throughput Screening • Cell Biology • Life Sciences • Clinical Development • Neurobiology • Drug Design • Cheminformatics • Hts • In Vitro • Cellular Biology • Omics • Biomedical Informatics • Cro Management

Ranks

Certificate: Health In Numbers: Quantitative Methods In Clinical & Public Health Research

Emails

a***[email protected]

Industries

Biotechnology

Resumes

Resumes

Berkley Lynch Photo 1

Vice President, Biology

View page
Location:
Cambridge, MA
Industry:
Biotechnology
Work:
Vigil Neuroscience
Vice President, Biology
Rodin Therapeutics
Senior Director Cns Biology
Dotmatics 2013 - Jan 2016
Solutions Specialist
Biotech/Pharma 2011 - 2013
Independent Consultant
Link Medicine Jan 2009 - Jul 2011
Vice President
Education:
University of California, Berkeley 2013 - 2016
University of California, Berkeley 1990 - 1993
The Rockefeller University 1984 - 1990
Doctorates, Doctor of Philosophy, Biochemistry, Chemistry Oberlin College 1977 - 1981
Bachelors, Bachelor of Arts, Chemistry
Skills:
Drug Discovery
Biochemistry
Molecular Biology
Biotechnology
Assay Development
Biomarkers
Pharmacology
Drug Development
Neuroscience
Pharmaceutical Industry
Cro
High Throughput Screening
Cell Biology
Life Sciences
Clinical Development
Neurobiology
Drug Design
Cheminformatics
Hts
In Vitro
Cellular Biology
Omics
Biomedical Informatics
Cro Management
Certifications:
Health In Numbers: Quantitative Methods In Clinical & Public Health Research

Publications

Us Patents

Methods For The Identification Of Agents For The Treatment Of Seizures, Neurological Diseases, Endocrinopathies And Hormonal Diseases

View page
US Patent:
7090985, Aug 15, 2006
Filed:
Dec 3, 2002
Appl. No.:
10/308163
Inventors:
Berkley Lynch - Cambridge MA, US
Karl Nocka - Cambridge MA, US
Bruno Fuks - Brussels, BE
Assignee:
UCB, S.A. - Brussels
International Classification:
G01N 33/53
C12P 21/06
US Classification:
435 71, 435 691
Abstract:
The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.

Methods For Identifying Agents That Bind A Levetiracetam Binding Site (Lbs) Or Compete With Lev Binding To A Lbs Of A Synaptic Vesicle Protein 2 (Sv2)

View page
US Patent:
7465549, Dec 16, 2008
Filed:
Dec 2, 2003
Appl. No.:
10/725189
Inventors:
Berkley Lynch - Cambridge MA, US
Karl Nocka - Cambridge MA, US
Bruno Fuks - Brussels, BE
Assignee:
UCB, S.A. - Brussels
International Classification:
G01N 33/53
G01N 33/567
G01N 33/00
C12P 21/06
US Classification:
435 71, 435 721, 435 772, 435 793, 435 691
Abstract:
The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.

Methods For The Identification Of Agents For The Treatment Of Seizures, Neurological Diseases, Endocrinopathies And Hormonal Diseases

View page
US Patent:
20070135514, Jun 14, 2007
Filed:
Dec 2, 2003
Appl. No.:
10/537512
Inventors:
Berkley Lynch - Cambridge MA, US
Karl Nocka - Harvard MA, US
Bruno Fuks - Bruxelles, BE
International Classification:
A61K 31/4015
US Classification:
514424000
Abstract:
The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.

Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20100160372, Jun 24, 2010
Filed:
Nov 13, 2009
Appl. No.:
12/618265
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 27/02
A61P 29/00
A61P 35/00
A61P 9/00
A61P 25/28
A61P 25/16
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA antagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Mitochondrial Disorders Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20100331363, Dec 30, 2010
Filed:
Apr 30, 2010
Appl. No.:
12/771221
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 25/00
A61P 29/00
A61P 9/00
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to cause an improvement in mitochondrial health in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Mitochondrial Disorders Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20110060005, Mar 10, 2011
Filed:
Apr 7, 2010
Appl. No.:
12/756052
Inventors:
CRAIG J. JUSTMAN - CAMBRIDGE MA, US
TOM N. GRAMMATOPOULOS - BOSTON MA, US
BERKLEY A. LYNCH - CAMBRIDGE MA, US
ZHIHUA LIU - CHEVY CHASE MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 9/00
A61P 25/28
A61P 29/00
A61P 35/00
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to stimulate mitophagy in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20110294794, Dec 1, 2011
Filed:
Nov 13, 2009
Appl. No.:
13/129360
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4174
A61K 31/4439
A61K 31/5513
A61K 31/4545
A61P 25/28
A61P 25/14
A61P 27/02
A61P 29/00
A61P 9/00
A61P 35/00
A61P 25/16
A61K 31/496
A61P 3/00
US Classification:
514221, 514400, 51425405, 514343, 514290
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Inhibitors Of Sh2-Mediated Processes

View page
US Patent:
57101299, Jan 20, 1998
Filed:
Feb 23, 1995
Appl. No.:
8/392646
Inventors:
Berkley A. Lynch - Cambridge MA
Manfred Weigele - Cambridge MA
Assignee:
Ariad Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 3804
C07K 510
US Classification:
514 18
Abstract:
This invention relates to compounds of formula: ##STR1## and pharmaceutically acceptable salts thereof, where A is H, R. sup. 1, --CO--R. sup. 1 or --CO--OR. sup. 1 where R. sup. 1 is a substituted or unsubstituted alkyl, heteroalkyl, aryl or heteroaryl group and J is H or NO. sub. 2. L-forms of the compounds are currently preferred, although D-forms and racemic mixtures are also encompassed by this invention.
Control profile
Berkley A Lynch from Cambridge, MA, age ~63 Get Report